Appelhans Dannielle 4
4 · Rubius Therapeutics, Inc. · Filed Aug 12, 2022
Insider Transaction Report
Form 4
Appelhans Dannielle
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2022-08-09+12,500→ 12,500 total - Sale
Common Stock
2022-08-10$0.80/sh−5,737$4,590→ 6,763 total - Exercise/Conversion
Restricted Stock Units
2022-08-09−12,500→ 37,500 total→ Common Stock (12,500 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
- [F3]The shares underlying the restricted stock units vest in four equal annual installments beginning on August 9, 2022.